Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke.
about
Blood Accessibility to Fibrin in Venous Thrombosis is Thrombus Age-Dependent and Predicts Fibrinolytic Efficacy: An In Vivo Fibrin Molecular Imaging Study.Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat?The Severity of Intracranial Hemorrhages Measured by Free Hemoglobin in the Brain Depends on the Anticoagulant Class: Experimental Data.Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation.Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis.Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association.The Long-Lasting Rodenticide Brodifacoum Induces Neuropathology in Adult Male Rats.Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation.Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke.Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.Rivaroxaban does not influence hemorrhagic transformation in a diabetes ischemic stroke and endovascular thrombectomy model.
P2860
Q30670224-164E6FE8-2E8C-4EC6-8B6F-DD1189C348C5Q38228428-DE1669F7-25D0-463E-AA18-16A669FBA66CQ38624770-9578B132-4AC4-4282-9A8B-CC3DB2887462Q38723869-A04F31EC-B848-4D89-B269-7D091389D79EQ38792322-9E640F7D-2241-4DCD-BE5A-6526CE08B535Q38851354-263C764F-1352-4360-ADBF-5928D3910B14Q38975409-164ED558-9324-4FF6-BB5D-6416CE90D153Q47807716-3D3B2049-8118-4F21-952C-34E1F89DC57AQ51039938-4E19E862-4968-4643-926F-34A31A56486AQ52691666-7CD01826-217E-47AB-A8CB-0350C970FF06Q53063628-5250A746-FBE2-4B27-8BEB-8DB3BCAF1B68Q55361115-55F190ED-5927-4015-A41E-D28DD0B23342
P2860
Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Rivaroxaban does not increase ...... experimental ischemic stroke.
@en
Rivaroxaban does not increase ...... experimental ischemic stroke.
@nl
type
label
Rivaroxaban does not increase ...... experimental ischemic stroke.
@en
Rivaroxaban does not increase ...... experimental ischemic stroke.
@nl
prefLabel
Rivaroxaban does not increase ...... experimental ischemic stroke.
@en
Rivaroxaban does not increase ...... experimental ischemic stroke.
@nl
P2093
P2860
P356
P1476
Rivaroxaban does not increase ...... experimental ischemic stroke.
@en
P2093
Ekkehart Jenetzky
Markus Zorn
Robert Ploen
Roland Veltkamp
Stefan Heitmeier
P2860
P304
P356
10.1038/JCBFM.2013.226
P577
2013-12-18T00:00:00Z